European Group on Ethics in Science and New Technologies

European Group on Ethics in Science and New Technologies
Name	European Group on Ethics in Science and New Technologies
Formation	1991
Headquarters	Brussels
Parent organization	European Commission
Purpose	Ethical advice on science and new technologies

Contents

European Group on Ethics in Science and New Technologies The European Group on Ethics in Science and New Technologies (EGE) is an advisory body established to provide independent ethical guidance to the European Commission, linking deliberations across European Union institutions such as the European Parliament and the Council of the European Union, while interacting with actors including the European Economic and Social Committee, the Committee of the Regions, the Organisation for Economic Co-operation and Development, and the United Nations Educational, Scientific and Cultural Organization. Its remit spans interfaces among stakeholders like the World Health Organization, the European Medicines Agency, the European Court of Justice, and national bodies exemplified by the Health Council of the Netherlands, the German Ethics Council, and the French National Consultative Ethics Committee for Health and Life Sciences. The group’s work connects major policy dossiers such as the Charter of Fundamental Rights of the European Union, the General Data Protection Regulation, and the Treaty of Lisbon while engaging with prominent figures from institutions including Max Planck Society, Institut Pasteur, Karolinska Institutet, and Wellcome Trust.

History

The inception of the group in 1991 followed initiatives by the European Commission under President Jacques Delors and drew on precedent from panels such as the Nuffield Council on Bioethics, the President's Council on Bioethics (United States), and advice mechanisms in the Council of Europe and the Organisation for Economic Co-operation and Development. Early membership and leadership involved academics and advisors linked to institutions including Oxford University, Cambridge University, Université Paris-Descartes, University of Milan, Leiden University, and KU Leuven, reflecting engagement with research funders like the European Research Council and programmes such as the Framework Programme and later Horizon 2020. Over successive Commission presidencies—Romano Prodi, José Manuel Barroso, Jean-Claude Juncker, and Ursula von der Leyen—the group’s mandate and composition were periodically updated, responding to emergent technologies flagged by actors like European Investment Bank, the European Patent Office, and the European Space Agency.

The group is mandated by the European Commission to issue "opinions" addressing ethical dimensions of dossiers including biotechnology, biomedical research linked to European Centre for Disease Prevention and Control, artificial intelligence concerns intersecting with the European Commission’s High-Level Expert Group on Artificial Intelligence, data governance resonant with the European Data Protection Supervisor, and human enhancement topics cross-referenced with the European Group on Ethics in Science and New Technologies's stakeholders. It functions to advise Commissioners such as those for Research, Science and Innovation and Health and Food Safety, to contribute to impact assessments used by the European Parliament and European Court of Auditors, and to convene dialogues with civil society organizations like Greenpeace, European Public Health Alliance, and industry representatives such as European Federation of Pharmaceutical Industries and Associations and DigitalEurope.

Members are appointed by the President of the European Commission and drawn from academia, civil society, industry, and ethics institutions affiliated with entities like Max Planck Institute for Innovation and Competition, The Hastings Center, Georgetown University, Sciences Po, TU Delft, and national academies such as the Royal Society, the Académie des sciences, and the Austrian Academy of Sciences. The bureau includes a chair and vice-chairs who liaise with Commission Directorates-General including DG Research and Innovation, DG CONNECT, and DG SANTE, while secretariat support is provided within structures related to the European Commission Representation in Belgium and task forces coordinate with programmes like Horizon Europe. Meetings have been held in locations tied to EU institutions, including Brussels, Strasbourg, and occasionally hosted alongside conferences at European University Institute and Berlin-Brandenburg Academy of Sciences and Humanities.

The group has produced opinions on cloning, stem cells, gene editing (notably CRISPR-Cas9 debates), data ethics relating to big data and health registries, governance of artificial intelligence, and the socio-ethical aspects of synthetic biology and nanotechnology, engaging with policy files such as the Clinical Trials Regulation and the In Vitro Diagnostic Regulation. Its outputs have been cited in documents from the European Parliament Committee on the Environment, Public Health and Food Safety, the European Economic and Social Committee, and in guidance by agencies like the European Medicines Agency and the European Food Safety Authority, and informed public consultations involving NGOs such as Médecins Sans Frontières and research funders like the Wellcome Trust and European Research Council.

Critiques have arisen from stakeholders including advocacy groups like Access Now and scholars affiliated with University College London and Université Libre de Bruxelles about composition, transparency, and alleged proximity to industry bodies such as European Federation of Pharmaceutical Industries and Associations, raising parallels to debates seen in dossiers involving the European Medicines Agency and the European Chemicals Agency. Academic critics from institutions such as Harvard University, Columbia University, and University of Oxford have questioned methodology and impact, while national ethics councils including the German Ethics Council and commentators from think tanks like the Bruegel and Chatham House have debated its role relative to parliamentary and judicial oversight, echoing tensions seen in cases before the European Court of Justice.

The group’s opinions have influenced legislative and regulatory work in fields including biotechnology, healthcare, and digital policy, informing regulators such as the European Medicines Agency and interinstitutional negotiations in the Trilogue process between the European Commission, European Parliament, and the Council of the European Union. Its advisory outputs have been referenced in impact assessments for Horizon Europe and in Commission communications linked to ethics frameworks used by agencies like the European Innovation Council and the European Data Protection Board, contributing to the EU’s positioning in international discussions with entities such as the United Nations, the World Health Organization, and the Organisation for Economic Co-operation and Development.

Category:Ethics organizations